We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
- Authors
Yamada, Yasuhide; Shirao, Kuniaki; Hyodo, Ichinosuke; Arai, Yasuaki; Denda, Tadamichi; Ambo, Tomonori; Ohtsu, Atsushi
- Abstract
<bold>Purpose: </bold>Experimental studies have shown that mitomycin C (MMC) acts synergistically with irinotecan. We evaluated the antitumor activity and toxicity of a combination of irinotecan and MMC in patients with metastatic colorectal cancer resistant to fluoropyrimidines.<bold>Methods: </bold>Eligible patients had evidence of tumor progression while receiving fluoropyrimidine-based regimens or had disease recurrence within 6 months after the completion of adjuvant treatment with fluoropyrimidines. Irinotecan (150 mg/m(2)) and MMC (5 mg/m(2)) were administered on days 1 and 15 of a 28-day cycle. Treatment was repeated every 4 weeks.<bold>Results: </bold>Among the 41 patients enrolled, 37 (90%) had received previous chemotherapy for metastatic disease, and 4 had received adjuvant chemotherapy alone. Objective responses were observed in 14 patients (34%, 95% confidence interval 20-49%). The median time to progression was 4.2 months, and the median survival time was 11.9 months. The study treatment was well tolerated; the median number of cycles received was four. Grade 3 or 4 neutropenia, the most common toxic effect, occurred in 20 patients (49%). Grade 3 or 4 thrombocytopenia occurred in four patients (10%) and grade 3 diarrhea in one patient.<bold>Conclusions: </bold>Our results suggest that irinotecan and MMC combination therapy is effective and well tolerated in patients with fluoropyrimidine-resistant metastatic colorectal cancer. Further clinical investigation of this regimen is warranted.
- Subjects
COLON cancer; FLUOROPYRIMIDINES; ORGANOFLUORINE compounds; PYRIMIDINES; ANTINEOPLASTIC agents; CAMPTOTHECIN; COLON tumors; COMPARATIVE studies; DRUG resistance in cancer cells; DOSE-effect relationship in pharmacology; FLUOROURACIL; RESEARCH methodology; MEDICAL cooperation; PROGNOSIS; RECTUM tumors; RESEARCH; EVALUATION research; DISEASE progression; MITOMYCINS
- Publication
Cancer Chemotherapy & Pharmacology, 2003, Vol 52, Issue 2, p125
- ISSN
0344-5704
- Publication type
journal article